Leerink Partnrs Has Negative Outlook of IDYA FY2026 Earnings

Key Points

• Leerink Partners has decreased its FY2026 earnings per share estimate for IDEAYA Biosciences from ($3.88) to ($4.05), indicating a more pessimistic outlook for the company's financial performance.
• The company reported a quarterly earnings per share of ($0.88), which missed analyst expectations of ($0.85), although it achieved higher revenue of $6 million compared to the $3.48 million expected.
• Despite the negative earnings outlook, multiple analysts have issued "buy" ratings for IDEAYA, with price targets ranging around $38 to $44, reflecting a generally optimistic view among market experts.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Research analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for IDEAYA Biosciences in a research report issued on Tuesday, September 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($4.05) per share for the year, down from their prior estimate of ($3.88). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences' FY2027 earnings at ($4.04) EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to analysts' expectations of $3.48 million. During the same period in the previous year, the business posted ($0.68) EPS. The company's revenue for the quarter was up NaN% compared to the same quarter last year.

Other analysts have also issued reports about the stock. Citigroup restated a "buy" rating on shares of IDEAYA Biosciences in a research note on Tuesday. Wells Fargo & Company began coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. Royal Bank Of Canada increased their price objective on shares of IDEAYA Biosciences from $36.00 to $38.00 and gave the company an "outperform" rating in a research report on Tuesday. Citizens Jmp assumed coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They set a "mkt outperform" rating and a $41.00 price objective for the company. Finally, JMP Securities began coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They set a "market outperform" rating and a $41.00 target price for the company. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $42.75.

IDEAYA Biosciences Price Performance

IDYA stock opened at $24.71 on Thursday. The business's 50-day moving average is $23.84 and its two-hundred day moving average is $20.70. The firm has a market capitalization of $2.17 billion, a P/E ratio of -6.52 and a beta of 0.12. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $37.80.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IDYA. CWM LLC grew its position in shares of IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after buying an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after acquiring an additional 1,546 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of IDEAYA Biosciences during the fourth quarter worth about $47,000. Signaturefd LLC grew its holdings in shares of IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after purchasing an additional 2,271 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEAYA Biosciences during the second quarter worth about $61,000. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.